ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
7 announcements with these filters
Sun Pharma delivered resilient double-digit revenue growth despite U.S. specialty headwinds, masking underlying margin pressure from lower Lenalidomide sales.
Sun Pharma reports Q1FY27 data showing diversified revenue of Rs 582 Bn for FY26. Key strategy remains scaling Innovative Medicines (22% of sales) and maintaining India market leadership (8.5% share).
Sun Pharma reported Q1FY27 revenue growth of 10.1% YoY to INR 151,836 million with an EBITDA margin of 28.9%. Growth was driven by Global Innovative Medicines and India formulations.
Sun Pharma delivered strong double-digit growth led by India and global specialty medicines, though US generics face erosion and increased competition.
Sun Pharma reported FY26 sales of Rs 582 Bn with a 30.3% EBITDA margin. Strategy focuses on expanding the Global Innovative Medicines portfolio and maintaining leadership in the Indian market.
Sun Pharma reports Q4FY26 revenue growth of 13.6% and FY26 sales of INR 582 billion. Strategy focuses on Global Innovative Medicines and integrating the Organon acquisition.
Sun Pharma delivered strong FY26 growth led by specialty medicines and India market share gains, despite US generic competition and regulatory headwinds.